[go: up one dir, main page]

BR9812127A - Arilpiridazinonas como inibidores da biossìntese de prostagleina endoperóxido h sintase - Google Patents

Arilpiridazinonas como inibidores da biossìntese de prostagleina endoperóxido h sintase

Info

Publication number
BR9812127A
BR9812127A BR9812127-8A BR9812127A BR9812127A BR 9812127 A BR9812127 A BR 9812127A BR 9812127 A BR9812127 A BR 9812127A BR 9812127 A BR9812127 A BR 9812127A
Authority
BR
Brazil
Prior art keywords
cox
inhibitors
prostaglein
endoperoxide
cyclooxygenase
Prior art date
Application number
BR9812127-8A
Other languages
English (en)
Inventor
Lawrence A Black
Anwer Basha
Teodozyjkolasa
Michael E Kort
Huaqing Liu
Catherine M Mccarty
Meena V Patel
Jeffrey J Rohde
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of BR9812127A publication Critical patent/BR9812127A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/18—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"ARILPIRIDAZINONAS COMO INIBIDORES DA BIOSSìNTESE DE PROSTAGLEINA ENDOPERóXIDO H SINTASE" A presente invenção divulga compostos de piridazinona, os quais são inibidores da ciclooxigenase (COX) e, em particular, são inibidores seletivos da ciclooxigenase-2 (COX/2). A COX-2 é a isoforma capaz de ser induzida associada com a inflamação, em oposição à isoforma constitutiva, a ciclooxigenase-1 (COX-1), que é uma enzima "zeladora" importante em muitos tecidos, incluindo o trato gastrointestinal (GI) e os rins. A seletividade destes compostos para a COX-2 minimiza os efeitos colaterais GI e renais não desejados, vistos com as drogas antiinflamatórias não-esteroidais (NSAIDs) atualmente vendidas.
BR9812127-8A 1997-08-22 1998-08-10 Arilpiridazinonas como inibidores da biossìntese de prostagleina endoperóxido h sintase BR9812127A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91702397A 1997-08-22 1997-08-22
PCT/US1998/016479 WO1999010331A1 (en) 1997-08-22 1998-08-10 Arylpyridazinones as prostaglandin endoperoxide h synthase biosynthesis inhibitors

Publications (1)

Publication Number Publication Date
BR9812127A true BR9812127A (pt) 2000-07-18

Family

ID=25438243

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9812127-8A BR9812127A (pt) 1997-08-22 1998-08-10 Arilpiridazinonas como inibidores da biossìntese de prostagleina endoperóxido h sintase

Country Status (8)

Country Link
EP (1) EP1007515A1 (pt)
BR (1) BR9812127A (pt)
CA (1) CA2299300C (pt)
CO (1) CO4970740A1 (pt)
SA (1) SA98190764B1 (pt)
TW (1) TWI232216B (pt)
WO (1) WO1999010331A1 (pt)
ZA (1) ZA987555B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525053B1 (en) * 1997-08-22 2003-02-25 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
US6307047B1 (en) * 1997-08-22 2001-10-23 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
HUP0100059A3 (en) 1997-11-19 2002-08-28 Kowa Co Novel pyridazine derivatives and drugs containing the same as the active ingredient
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
AU756275B2 (en) 1998-08-14 2003-01-09 Nihon Nohyaku Co., Ltd. Pyridazinone derivatives
CN1279026C (zh) * 1998-10-27 2006-10-11 艾博特公司 前列腺素内过氧化物h合酶生物合成抑制剂
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
JP2000247959A (ja) 1999-02-26 2000-09-12 Kowa Co ピリダジン−３−オン誘導体及びこれを含有する医薬
EP1175214B1 (en) 1999-12-08 2004-11-24 Pharmacia Corporation Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
IL150368A0 (en) 1999-12-23 2002-12-01 Nitromed Inc Nitrosated and nitrosylated cyclooxygenase-2-inhibitors, compositions and methods of use
US6664256B1 (en) 2000-07-10 2003-12-16 Kowa Co., Ltd. Phenylpyridazine compounds and medicines containing the same
ITMI20010733A1 (it) 2001-04-05 2002-10-05 Recordati Chem Pharm Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
JP2005519895A (ja) * 2002-01-18 2005-07-07 ファルマシア・コーポレーション Ｐ３８阻害剤としての置換ピリダジノン
AU2003279622A1 (en) 2002-06-28 2004-01-19 Nitromed, Inc. Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use
MXPA05009972A (es) 2003-03-18 2005-11-04 Kowa Co Derivado de fenilpiridazina soluble en agua y medicina que contiene el mismo.
PL2266585T3 (pl) 2003-05-07 2013-10-31 Osteologix As Rozpuszczalne w wodzie sole stronktu do stosowania w leczeniu chorób chrząstki i/lub kości
WO2005007632A1 (en) * 2003-07-18 2005-01-27 Pharmacia Corporation Substituted pyridazinones as inhibitors of p38
DE602005014359D1 (de) 2004-06-09 2009-06-18 Sumitomo Chemical Co Pyridazinverbindung und deren verwendung
WO2006001175A1 (ja) 2004-06-28 2006-01-05 Sumitomo Chemical Company, Limited ピリダジン化合物及びその用途
PT1928454E (pt) 2005-05-10 2014-12-04 Intermune Inc Derivativos da piridona para modulação do sistema de proteína quinase ativada pelo stress
EP1932840B1 (en) * 2005-10-03 2014-04-09 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compound and pharmaceutical application thereof
US8022073B2 (en) 2005-12-07 2011-09-20 Sumitomo Chemical Company, Limited Substituted pyridazine compounds and fungicidal uses thereof
AU2006322707B2 (en) 2005-12-07 2011-09-15 Sumitomo Chemical Company, Limited Pyridazine compound and use thereof
DE102007008843A1 (de) 2007-02-23 2008-08-28 Bayer Healthcare Ag Verfahren zur Herstellung von 4,5-Dihalogen-2-aryl-2H-pyridazin-3-onen
DE102007008840A1 (de) 2007-02-23 2008-08-28 Bayer Healthcare Ag Neue polymorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-methyl-1-butoxy)-5-[4-methylsulfonyl)phenyl]-3(2H)-pyridazinon (FHMP)
DE102007008839A1 (de) 2007-02-23 2008-08-28 Bayer Healthcare Ag Verfahren zur Herstellung von 4-(3-Hydroxy-3-methyl-butoxy)-5-[4-(methylsulfonyl)phenyl]-2-arylpyridazin-3(2H)-onen
DE102007020690A1 (de) 2007-05-03 2008-11-06 Bayer Healthcare Ag Neue amorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-mehtyl-1-butoxy)-6[4-methylsulfonyl)phenyl]-3(2H)-pyridazinon (FHMP)
DE102007020689A1 (de) 2007-05-03 2008-11-06 Bayer Healthcare Ag Neue polymorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-methyl-1-butoxy-5-[4-methylsulfonyl)phenyl]3/2H)-pyridazinon (FHMP)
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
AP2014007637A0 (en) 2011-11-15 2014-05-31 Takeda Pharmaceutical Dihydroxy aromatic heterocyclic compound
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
WO2015153683A1 (en) 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones
JP7096598B2 (ja) 2016-09-07 2022-07-06 トラスティーズ オブ タフツ カレッジ イムノｄａｓｈ阻害剤及びｐｇｅ２アンタゴニストを用いた併用療法
CA3209491A1 (en) 2021-03-15 2022-09-22 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988009675A1 (en) * 1987-06-05 1988-12-15 Medicis Corporation Inhibition of arachidonic acid metabolism
IL115889A0 (en) * 1994-11-14 1996-01-31 Rohm & Haas Pyridazinones and their use as fungicides
US5622948A (en) * 1994-12-01 1997-04-22 Syntex (U.S.A.) Inc. Pyrrole pyridazine and pyridazinone anti-inflammatory agents

Also Published As

Publication number Publication date
TWI232216B (en) 2005-05-11
CA2299300C (en) 2007-04-17
WO1999010331A1 (en) 1999-03-04
SA98190764B1 (ar) 2006-08-06
ZA987555B (en) 1999-02-23
EP1007515A1 (en) 2000-06-14
CA2299300A1 (en) 1999-03-04
CO4970740A1 (es) 2000-11-07

Similar Documents

Publication Publication Date Title
BR9812127A (pt) Arilpiridazinonas como inibidores da biossìntese de prostagleina endoperóxido h sintase
BR9914858A (pt) Inibidores de biosìntese sintase h de endoperóxido de prostaglandina
ATE319691T1 (de) Prostaglandin endoperoxyde h synthase biosynthese inhibitoren
Grishanova et al. Aryl hydrocarbon receptor in oxidative stress as a double agent and its biological and therapeutic significance
Bhutia et al. Amino acid transporters in cancer and their relevance to “glutamine addiction”: novel targets for the design of a new class of anticancer drugs
Velázquez et al. Novel nonsteroidal antiinflammatory drugs possessing a nitric oxide donor diazen-1-ium-1, 2-diolate moiety: design, synthesis, biological evaluation, and nitric oxide release studies
Lolli et al. A new class of ibuprofen derivatives with reduced gastrotoxicity
BRPI0011172B8 (pt) derivados do 4,5-diaril-3(2h)-furanona como inibidores de ciclooxigenase-2
Ramalho et al. The search for new COX-2 inhibitors: a review of 2002–2008 patents
Rasooli et al. Synergistic effects of deuterium depleted water and Mentha longifolia L. essential oils on sepsis-induced liver injuries through regulation of cyclooxygenase-2
Huguenin et al. Evaluation of the antitumoral potential of different nitric oxide-donating non-steroidal anti-inflammatory drugs (NO-NSAIDs) on human urological tumor cell lines
Herschman et al. Cyclooxygenase 2 (COX-2) as a target for therapy and noninvasive imaging
Thyagarajan et al. Acetylsalicylic acid inhibits the growth of melanoma tumors via SOX2-dependent-PAF-R-independent signaling pathway
Chen et al. Discovery of dual target inhibitors against cyclooxygenases and leukotriene A4 hydrolyase
Biava Introduction to COX inhibitors
Theoduloz et al. Inhibition of key enzymes in the inflammatory pathway by hybrid molecules of terpenes and synthetic drugs: In vitro and in silico studies
TR200000478T2 (tr) Prostaglandin endoperoksit H sentaz biyosentezi inhibitörleri olarak arilpiridazinonlar.
Hightower et al. Farnesylation of nonpeptidic thiol compounds by protein farnesyltransferase
Pham et al. Biological evaluation and molecular docking study of 3-(4-sulfamoylphenyl)-4-phenyl-1H-pyrrole-2, 5-dione as COX-2 inhibitor
Miura Reactivity of nonsteroidal anti-inflammatory drugs with peroxidase: a classification of nonsteroidal anti-inflammatory drugs
Dammann Preferential COX-2 inhibition: its clinical relevance for gastrointestinal non-steroidal anti-inflammatory rheumatic drug toxicity
Rowland et al. Pharmacological characterization of a selective COX-2 inhibitor MF-tricyclic,[3-(3, 4-difluorophenyl)-4-(4-(methylsulfonyl) phenyl)-2-(5H)-furanone], in multiple preclinical species
Gülcan et al. Marginally designed new profen analogues have the potential to inhibit cyclooxygenase enzymes
Dudek et al. TR-FRET biochemical assays for detecting posttranslational modifications of p53
Nesci et al. The inhibition of the mitochondrial F1FO-ATPase activity when activated by Ca2+ opens new regulatory roles for NAD+

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE DIANTE DO QUE FOI EXPOSTO, OPINO POR NAO ACOLHER A PRESENTACAO DO INTERESSADO E, CONSIDERANDO QUE NAO FORAM APRESENTADOS ARGUMENTOS PERTINENTES, CONCLUI- SE QUE O PEDIDO EM LIDE NAO APRESENTA REQUISITOS QUE JUSTIFIQUEM O SEU REEXAME

B12B Appeal against refusal [chapter 12.2 patent gazette]